Location Directory

Clinical trials in Orlando, Florida

This page shows live ClinicalTrials.gov search results for Orlando, Florida, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 7:45 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

6874

Shown on this page

Current sort

Live official records

Open in full search

Conditions: Small Cell Lung Cancer
Interventions: ABBV-706, Topotecan, Lurbinectedin, Amrubicin; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 531 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 37
States / cities: Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 32 more

Conditions: Childhood-Onset Fluency Disorder (Stuttering)
Interventions: Ecopipam, Placebo; Drug
Lead sponsor: Emalex Biosciences Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 9
States / cities: Riverside, California • Santa Ana, California • Jacksonville, Florida + 6 more

Conditions: Hypertension, Pulmonary
Interventions: Sotatercept 0.3 mg/kg, Placebo, Sotatercept 0.3 mg/kg escalating to 0.7 mg/kg; Drug
Lead sponsor: Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 165 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 56
States / cities: Phoenix, Arizona • Tucson, Arizona • La Jolla, California + 46 more

Conditions: Metastatic Colorectal Cancer
Interventions: Telisotuzumab Adizutecan; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 74 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 24
States / cities: Duarte, California • Irvine, California • Los Angeles, California + 20 more

Conditions: Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
Interventions: Biospecimen Collection, Carboplatin, Etoposide, Filgrastim, Ifosfamide, Magnetic Resonance Imaging, Mesna, Pegfilgrastim, Peripheral Blood Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Second-Look Surgery, Thiotepa; Procedure · Drug · Biological + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 3 Years to 29 Years
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 152
States / cities: Birmingham, Alabama • Anchorage, Alaska • Mesa, Arizona + 120 more

Conditions: Bipolar I or II Disorder
Interventions: ABBV-932; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 47
States / cities: Phoenix, Arizona • Anaheim, California • Colton, California + 41 more

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Pevonedistat, Venetoclax, Azacitidine; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 23
States / cities: Gilbert, Arizona • La Jolla, California • Orange, California + 20 more

Conditions: Coronary Artery Disease, Coronary Artery Disease Risk High, Complex Coronary Artery Disease
Interventions: IVUS; Device
Lead sponsor: ECRI bv; Industry
Eligibility: 18 Years and older
Enrollment: 1,010 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 18
States / cities: Phoenix, Arizona • Loma Linda, California • Coral Gables, Florida + 12 more

Conditions: Prostate Cancer
Interventions: Investigators choice of SoC, AAA817; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years · Male only
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2033
U.S. locations: 35
States / cities: Scottsdale, Arizona • Los Angeles, California • Palo Alto, California + 30 more

Conditions: Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid Tumors
Interventions: Sunitinib (CLOSED TO ENROLLMENT), Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT), Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT), Olaparib (CLOSED TO ENROLLMENT), Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT), Abemaciclib (CLOSED TO ENROLLMENT), Talazoparib (CLOSED TO ENROLLMENT), Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT), Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT), Futibatinib, Dabrafenib plus Trametinib, Fam-Trastuzumab Deruxtecan-Nxki (TDxD); Drug
Lead sponsor: American Society of Clinical Oncology; Other
Eligibility: 12 Years and older
Enrollment: 4,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 174
States / cities: Birmingham, Alabama • Phoenix, Arizona • Auburn, California + 137 more

Conditions: Irritable Bowel Syndrome With Constipation (IBS-C)
Interventions: Tenapanor 50 MG, Tenapanor 25 mg bid, Placebo; Drug
Lead sponsor: Ardelyx; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 39
States / cities: Foley, Alabama • Tucson, Arizona • Little Rock, Arkansas + 34 more

Conditions: Smoking
Interventions: Brenipatide, Placebo; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 222 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 18
States / cities: Rogers, Arkansas • DeLand, Florida • Hollywood, Florida + 15 more

Clinical trials in Orlando, Florida

Filter and sort this location

Live official records

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Effects of Ecopipam or Placebo in Adults With Stuttering (Speak Freely)

A Study of Sotatercept for the Treatment of Cpc-PH Due to HFpEF (MK-7962-007/A011-16)

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Study to Assess the Adverse Events of Oral ABBV-932 in Adult Participants With Depressive Episodes Associated With Bipolar I or II Disorder

A Study of Pevonedistat and Venetoclax Combined With Azacitidine to Treat Acute Myeloid Leukemia (AML) in Adults Unable to Receive Intensive Chemotherapy

IVUS CHIP UPP Registry

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Study to Assess Safety and Efficacy of Tenapanor for Treatment of IBS-C in Pediatric Patients 12 to Less Than 18 Years

A Study of Brenipatide in Adults Who Quit Smoking Cigarettes and Want to Avoid Relapse